Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Glioblastoma, Prostate cancer, Squamous Cell Carcinoma of the Head and Neck | Access and Reimbursement | US | 2016
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015
The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…
The Burgeoning Prostate Cancer Market in the EU5 | Physician & Payer Forum | EU5 | 2015
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
Global Forecast of the Coming Ten Years in the Epidemiology and Treatment Opportunities for Prostate Cancer
Over the next ten years, more than 15 million men worldwide will be diagnosed with prostate cancer, resulting in nearly 3 million first-line drug-treatment opportunities in the metastatic castrate-…
